Etoposide

Crizotinib, alectinib, ceritinib, paclitaxel, pemetrexed, etoposide, luminespib (AUY922) and lorlatinib (PF-06463922) were purchased from ChemieTek (Indianapolis, IN). Ganetispib was purchased from Selleckchem (Houston, TX). Retaspimycin hydrochloride (IPI504) was purchased from Apexbio (Houston, TX).

Stable shNOX4 or vector control RCC 786-O cells were mixed with matrigel and injected into 6-week-old male athymic nude (BALB/c, nu/nu) mice as described^{13 (link)}. Briefly, shVector was injected to the left flank and shNOX4 to the right flank of the same mouse. Two independent vectors and two independent shNOX4 clones were injected into 10 mice per group. To examine the effects of etoposide in RCC shVector and shNOX4 injected nude mice, we delivered four consecutive intraperitoneal (IP) injections of etoposide (Chemietek ct-eph) (12 mg/kg/day) for a total of 4 days. The tumors were measured prior to etoposide delivery and at the end of the experiment (5 days after last etoposide injection). The tumors were measured again at the end of the experiment and the difference between tumor volume at the start and end were graphed normalized to 1, which indicates the start volume. Mice were then killed and the tumors excised and snap-frozen. All experiments using mice were approved by the University of Texas Health Science Center at San Antonio Institutional Animal Care and Use Committee.